beta

ACER

Acer Therapeutics, Inc.

Acer

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Edsivo and ACER-001. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded by Christopher Schelling in September 2017 and is headquartered in Newton, MA.

Market Cap: 37 Million

Primary Exchange: NASDAQ

Website: http://www.acertx.com

Shares Outstanding: 10.1 Million

Float: 4.87 Million

Dividend: (%)

Beta: 2.08692423847345

Sector: Health Technology

Industry: Pharmaceuticals: Major

Ethical Flags

Animal testing

Longest drawdown: 1733 trading days

From: 2013-02-05 To: 2019-12-06

Lowest Point:

Acer Therapeutics: Concerns Prior To Upcoming PDUFA Date

via: SeekingAlpha at 2019-06-11 12:00:30:000

Acer Therapeutics Inc. (ACER) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts, focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening orphan or ultra-orphan diseases with significant unmet… read more...

Acer Therapeutics: Concerns Prior To Upcoming PDUFA Date

via: SeekingAlpha at 2019-06-11 12:00:30:000

Acer Therapeutics Inc. (ACER) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts, focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening orphan or ultra-orphan diseases with significant unmet… read more...

Acer Therapeutics: Concerns Prior To Upcoming PDUFA Date

via: SeekingAlpha at 2019-06-11 12:00:30:000

Acer Therapeutics Inc. (ACER) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts, focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening orphan or ultra-orphan diseases with significant unmet… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2017-09-21 10.355527 1.0 10.355527
2015-09-29 8.0 1.0 8.0
Data provided by IEX Cloud